非感染性葡萄膜炎患者中抗肿瘤坏死因子α抑制剂抗药抗体研究
该回顾性横断面研究纳入54例接受阿达木单抗或英夫利西单抗治疗并检测血清药物浓度及抗药抗体的非感染性葡萄膜炎患者。阿达木单抗组抗药抗体频率为35.7%,抗药抗体存在与较低药物浓度相关,较高抗药抗体水平与治疗失败风险增加相关。作者认为,尽管受回顾性设计限制,对治疗失败患者可考虑治疗药物监测以排除抗药抗体作为治疗失败的可能原因。
要点
- 阿达木单抗组抗药抗体频率为35.7%(15/42例),英夫利西单抗组未检测到抗药抗体。
- 阿达木单抗组有抗药抗体者平均药物浓度低于无抗药抗体者(2.8 μg/mL vs 13.6 μg/mL,P < .001)。
- 良好临床反应与药物浓度高于2.7 μg/mL或抗体水平低于15.2 μg/mL相关。
核心结论
- 本研究显示35.7%接受阿达木单抗治疗的非感染性葡萄膜炎患者存在抗药抗体。
- 抗药抗体的存在与较低药物浓度相关,较高抗药抗体水平与肿瘤坏死因子抑制剂治疗失败风险增加相关。
- 尽管受回顾性设计限制,作者认为对经历治疗失败的患者可考虑治疗药物监测,以帮助排除抗药抗体作为治疗失败的可能原因。
研究设计与样本
- 本研究为回顾性横断面研究,纳入2017年9月至2021年7月在美国国家眼科研究所诊断为非感染性葡萄膜炎并接受阿达木单抗或英夫利西单抗治疗、且进行了血清药物浓度和抗药抗体检测的患者。
- 共纳入54例患者,其中42例接受阿达木单抗(平均[SD]年龄43.6[19.6]岁;25例[59.5%]女性),12例接受英夫利西单抗(平均[SD]年龄42.7[20.4]岁;7例[58.3%]男性)。
- 暴露为血清药物浓度检测并反射性检测抗药抗体水平。
主要发现
- 阿达木单抗组平均(SD)药物浓度为9.72(6.82)μg/mL,平均(SD)抗药抗体水平为84.2(172.9)任意单位/mL,抗药抗体频率为35.7%(15/42例)。
- 阿达木单抗组有抗药抗体者平均药物浓度低于无抗药抗体者(平均[SD],2.8[2.6]μg/mL vs 13.6[5.2]μg/mL;差值:10.8μg/mL;95%CI,8.3-13.2μg/mL;P < .001)。
- 阿达木单抗组联合使用抗代谢药者平均药物浓度高于单药治疗者(平均[SD],11.0[7.3]μg/mL vs 6.8[4.5]μg/mL;差值:-4.2μg/mL;95%CI,-8.7至0.2μg/mL;P = .06)。
- 多变量模型显示,抗药抗体每增加1任意单位,平均药物浓度差异为-0.02μg/mL(95%CI,-0.01至-0.34μg/mL;P < .001)。
- 良好临床反应与药物浓度阈值高于2.7μg/mL或抗体水平低于15.2μg/mL相关;英夫利西单抗组平均(SD)药物浓度为27.02(18.15)μg/mL,未检测到抗药抗体。
关键数值与推荐
- 阿达木单抗组抗药抗体频率为35.7%(15/42例)。
- 阿达木单抗组有抗药抗体者平均药物浓度为2.8μg/mL,无抗药抗体者为13.6μg/mL(差值10.8μg/mL;95%CI,8.3-13.2μg/mL;P < .001)。
- 良好临床反应与药物浓度高于2.7μg/mL或抗体水平低于15.2μg/mL相关。
- 英夫利西单抗组平均药物浓度为27.02μg/mL,未检测到抗药抗体。
临床怎么用
- 作者认为,尽管受回顾性设计限制,对经历治疗失败的患者可考虑治疗药物监测,以帮助排除抗药抗体作为治疗失败的可能原因。
局限性
- 原文指出,本研究受回顾性设计限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Tumor necrosis factor inhibitors (TNFis) can induce antidrug antibody (ADA) formation and loss of therapeutic response. However, the utility of ADA testing and the association between ADAs and treatment response in patients with noninfectious uveitis (NIU) is not well understood. OBJECTIVE: To assess the frequency of ADAs and their association with drug levels and clinical response in patients with NIU treated with adalimumab or infliximab. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cross-sectional study included patients diagnosed with NIU who received adalimumab or infliximab and underwent testing for serum drug level and ADAs at the National Eye Institute from September 2017 to July 2021. EXPOSURES: Serum drug level testing with reflex testing for ADA levels was performed. MAIN OUTCOMES AND MEASURES: The main outcome was the association between drug levels and ADAs, clinical response, and concurrent antimetabolite use in patients treated with TNFis for NIU. RESULTS: Of 54 patients included in the study, 42 received adalimumab (mean [SD] age, 43.6 [19.6] years; 25 [59.5%] female) and 12 received infliximab (mean [SD] age, 42.7 [20.4] years; 7 [58.3%] male). In the adalimumab group, mean (SD) drug level was 9.72 (6.82) μg/mL, mean (SD) ADA level was 84.2 (172.9) arbitrary units/mL, and ADA frequency was 35.7% (15 of 42 patients). Mean drug level was lower in those with ADAs compared with those without ADAs (mean [SD], 2.8 [2.6] μg/mL vs 13.6 [5.2] μg/mL; difference: 10.8 μg/mL; 95% CI, 8.3-13.2 μg/mL; P < .001). There was a higher mean drug level with concurrent antimetabolite use compared with monotherapy (mean [SD], 11.0 [7.3] μg/mL vs 6.8 [4.5] μg/mL; difference: -4.2 μg/mL; 95% CI, -8.7 to 0.2 μg/mL; P = .06). Multivariable modeling showed that a 1-arbitrary unit increase in ADAs was associated with a -0.02 μg/mL (95% CI, -0.01 to -0.34 μg/mL) difference in mean drug level (P < .001). Favorable clinical response was associated with a threshold drug level above 2.7 μg/mL or an antibody level below 15.2 μg/mL. The mean (SD) drug level in the infliximab group was 27.02 (18.15) μg/mL, and no ADAs were detected. CONCLUSIONS AND RELEVANCE: In this study, 35.7% of adalimumab-treated patients with NIU had ADAs. The presence of ADAs was associated with lower drug levels, and higher ADA levels were associated with increased risk of TNFi treatment failure. Although limited by the retrospective design, our results suggest that therapeutic drug monitoring may be considered among patients experiencing therapy failure to help exclude ADAs as a potential cause of treatment failure.
引用
- Bellur S, McHarg M, Kongwattananon W, et al. Antidrug Antibodies to Tumor Necrosis Factor α Inhibitors in Patients With Noninfectious Uveitis. JAMA Ophthalmol. 2023. PMID: 36547953. doi:10.1001/jamaophthalmol.2022.5584
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。